| Dr Firoozeh Isfahani, MD | |
|
5555 W. Thunderbird, Banner Thunderbird Medical Center, Glendale, AZ 85306 | |
| (602) 865-2627 | |
| (602) 865-2631 |
| Full Name | Dr Firoozeh Isfahani |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 28 Years |
| Location | 5555 W. Thunderbird, Glendale, Arizona |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1568729374 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 50370 (Arizona) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Banner Thunderbird Medical Center | Glendale, AZ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Banner Hospital Based Physicians Arizona Llc | 3274782487 | 398 |
News Archive
ChemRisk, a leading scientific consulting firm, was asked by the Corn Refiners Association (CRA) to examine the recent publication by Institute for Agriculture and Trade Policy (IATP), "Not So Sweet: Missing Mercury and High Fructose Corn Syrup," and the Environmental Health journal publication "Mercury from chlor-alkali plants: measured concentrations in food product sugar," by Dufault et al, 2009, and to offer our comments and analysis.
Veloxis Pharmaceuticals A/S announced today that the U.S. Food and Drug Administration has informed Veloxis of the tentative approval of Envarsus XR. FDA stated that the final approval of Envarsus XR will be delayed until expiration of the exclusivity period for Astellas' Astagraf XL.
DiscoveryBioMed, Inc. (DBM) today announced that it has been awarded a $750,000 Small Business Innovations Research (SBIR) Phase 2 grant by the National Institutes of Health (NIH) to continue the research into the discovery and development of small molecules to alleviate multiple chronic human diseases including cystic fibrosis (CF), hypertension and chronic kidney diseases with hypertension.
With only incremental improvements in ovarian cancer survival over the last 40 years, there is a clear need for new treatment options with long-lasting results. Many researchers have turned toward the development of immunotherapies that direct T-cells to selectively eliminate ovarian tumor cells, but an appropriate therapeutic target for ovarian cancers has remained elusive.
Academic and Community Cancer Research United (ACCRU) today announced the opening of a two-arm, randomized phase III, FDA registration trial of eribulin compared to standard weekly paclitaxel as first- or second-line chemotherapy for individuals with human epidermal growth factor receptor 2 (HER2) negative, locally recurrent, unresectable or metastatic breast cancer.
› Verified 1 days ago
| Entity Name | Banner Hospital Based Physicians Arizona Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275889891 PECOS PAC ID: 3274782487 Enrollment ID: O20121003000752 |
News Archive
ChemRisk, a leading scientific consulting firm, was asked by the Corn Refiners Association (CRA) to examine the recent publication by Institute for Agriculture and Trade Policy (IATP), "Not So Sweet: Missing Mercury and High Fructose Corn Syrup," and the Environmental Health journal publication "Mercury from chlor-alkali plants: measured concentrations in food product sugar," by Dufault et al, 2009, and to offer our comments and analysis.
Veloxis Pharmaceuticals A/S announced today that the U.S. Food and Drug Administration has informed Veloxis of the tentative approval of Envarsus XR. FDA stated that the final approval of Envarsus XR will be delayed until expiration of the exclusivity period for Astellas' Astagraf XL.
DiscoveryBioMed, Inc. (DBM) today announced that it has been awarded a $750,000 Small Business Innovations Research (SBIR) Phase 2 grant by the National Institutes of Health (NIH) to continue the research into the discovery and development of small molecules to alleviate multiple chronic human diseases including cystic fibrosis (CF), hypertension and chronic kidney diseases with hypertension.
With only incremental improvements in ovarian cancer survival over the last 40 years, there is a clear need for new treatment options with long-lasting results. Many researchers have turned toward the development of immunotherapies that direct T-cells to selectively eliminate ovarian tumor cells, but an appropriate therapeutic target for ovarian cancers has remained elusive.
Academic and Community Cancer Research United (ACCRU) today announced the opening of a two-arm, randomized phase III, FDA registration trial of eribulin compared to standard weekly paclitaxel as first- or second-line chemotherapy for individuals with human epidermal growth factor receptor 2 (HER2) negative, locally recurrent, unresectable or metastatic breast cancer.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Firoozeh Isfahani, MD 5555 W. Thunderbird, Banner Thunderbird Medical Center, Glendale, AZ 85306 Ph: (602) 865-2627 | Dr Firoozeh Isfahani, MD 5555 W. Thunderbird, Banner Thunderbird Medical Center, Glendale, AZ 85306 Ph: (602) 865-2627 |
News Archive
ChemRisk, a leading scientific consulting firm, was asked by the Corn Refiners Association (CRA) to examine the recent publication by Institute for Agriculture and Trade Policy (IATP), "Not So Sweet: Missing Mercury and High Fructose Corn Syrup," and the Environmental Health journal publication "Mercury from chlor-alkali plants: measured concentrations in food product sugar," by Dufault et al, 2009, and to offer our comments and analysis.
Veloxis Pharmaceuticals A/S announced today that the U.S. Food and Drug Administration has informed Veloxis of the tentative approval of Envarsus XR. FDA stated that the final approval of Envarsus XR will be delayed until expiration of the exclusivity period for Astellas' Astagraf XL.
DiscoveryBioMed, Inc. (DBM) today announced that it has been awarded a $750,000 Small Business Innovations Research (SBIR) Phase 2 grant by the National Institutes of Health (NIH) to continue the research into the discovery and development of small molecules to alleviate multiple chronic human diseases including cystic fibrosis (CF), hypertension and chronic kidney diseases with hypertension.
With only incremental improvements in ovarian cancer survival over the last 40 years, there is a clear need for new treatment options with long-lasting results. Many researchers have turned toward the development of immunotherapies that direct T-cells to selectively eliminate ovarian tumor cells, but an appropriate therapeutic target for ovarian cancers has remained elusive.
Academic and Community Cancer Research United (ACCRU) today announced the opening of a two-arm, randomized phase III, FDA registration trial of eribulin compared to standard weekly paclitaxel as first- or second-line chemotherapy for individuals with human epidermal growth factor receptor 2 (HER2) negative, locally recurrent, unresectable or metastatic breast cancer.
› Verified 1 days ago
Ipuole Paulinus Ogar, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 5555 W Thunderbird Rd, Glendale, AZ 85306 Phone: 602-865-2627 Fax: 602-865-2632 | |
Shiva Shojaie, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 5555 W Thunderbird Rd, Glendale, AZ 85306 Phone: 602-865-5555 | |
Dr. Veenu Gill, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 5620 W Thunderbird Rd, Glendale, AZ 85306 Phone: 602-795-7256 Fax: 602-795-7257 | |
Michael Best, M.D., MPH Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 5555 W Thunderbird Rd, Glendale, AZ 85306 Phone: 602-865-5555 | |
Hasan Chaudhry, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 20118 N 67th Ave Ste 300-415, Glendale, AZ 85308 Phone: 602-736-8386 | |
Dr. Matthew Brownell, D.O. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 5555 W, Thunderbird, Banner Thunderbird Medical Center, Glendale, AZ 85306 Phone: 602-865-2627 Fax: 602-865-2632 |